Cognate BioServices, a Memphis, Tenn.-based contract development and manufacturing organization (CDMO) specialized in cell and cell-mediated gene therapy products, acquired Cobra Biologics (Cobra), a CDMO specialized in providing manufacturing services for plasmid DNA and viral vector.
The company will continue to be supported by its existing investors. EW Healthcare Partners and Medivate Partners participated in this round of funding for the acquisition of Cobra, and Blackrock and the sovereign wealth fund will also continue to partner with the company.
The transaction creates an enhanced services provider delivering drug development and manufacturing solutions to the global cell and gene immunotherapy and regenerative medicine industries.
Led by J. Kelly Ganjei, CEO, Cognate is a dynamic, results-driven, organization focused on providing the broadest range of commercialization services to regenerative medicine, cellular immunotherapy and advance cell therapy companies. Cognate provides a combination of custom services to companies across all points of clinical and commercial development specializing in mid to late stage clinical trials and supporting clients through product scale-up into commercial manufacturing.
Led by Peter Coleman, CEO, Cobra Biologics is an international advanced therapy CDMO with GMP approved facilities in both Sweden and the UK each with an extensive track record in serving our global client base. The company offers a broad range of integrated and stand-alone services for both the clinical and commercial market.